Navigation Links
Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
Date:1/31/2013

FLEMINGTON, N.J., Jan. 31, 2013 /PRNewswire/ -- Arno Therapeutics, Inc. (OTCBB: ARNI), a clinical-stage biopharmaceutical company focused on the development of oncology therapeutics, today announced the appointment of Mr. Randy Thurman to its Board of Directors. With over 30 years of health care industry experience, Mr. Thurman brings a wealth of operational, financial, and business development expertise to Arno.  

"We are extremely pleased to welcome Mr. Thurman to our Board of Directors," said Glenn Mattes , CEO of Arno. "With his extensive knowledge, broad industry network, and history of strong leadership, we are confident that Mr. Thurman will provide Arno with invaluable guidance as we continue the development of our company and its exciting clinical stage assets."

Mr. Thurman became an Operating Partner for AEA Investors LP in October 2012 and previously held the same role with New Mountain Capital LLC since 2008. Mr. Thurman is also Executive Chairman of CogentHMG and was previously Founder, Chairman & CEO of VIASYS Healthcare, Inc., a global leader in respiratory, neurological and medical/surgical technologies. VIASYS Healthcare Inc. was acquired in a transaction which represented a four-fold increase in enterprise value over the five years the company was public. VIASYS was named by Smart Money magazine as one of the "10 Best Investments of the Decade," and Mr. Thurman was named an Ernst & Young Entrepreneur of the Year in 2007. Prior to joining VIASYS Healthcare Inc., Mr. Thurman was CEO of Strategic Reserves, LLC, which provided strategic leadership and M&A advisory services to bio-pharmaceutical, genomic and medical device companies. As Chairman of the Board of Enzon Inc., Mr. Thurman guided the company's growth from a $70 million market capitalization to over $2.5 billion. Previously, he was Chairman & CEO of Corning
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
2. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
3. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
4. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
5. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Regulus Appoints Mark G. Foletta to its Board of Directors
11. Synteract Appoints Keith Kelson as Chief Financial Officer and Member of Executive Council and Philip Doren, Ph.D., as Vice President, Biometrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
(Date:9/22/2014)... Sept. 22, 2014 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ... developing premium quality medical marijuana products, is pleased to ... ("Thunderbird"), has signed a definitive lease agreement for a ... BC.  The facility has 28,966 square feet of floor ... feet of mezzanine space for a total of approximately ...
(Date:9/22/2014)... CENTER VALLEY, Pa. , Sept. 22, 2014 ... and delivering innovative solutions for medical and surgical ... has reached a deal with Munich ... distributor of Kick ® Navigation. This agreement ... maintain distribution for cross-disciplinary U.S. sales and all ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... SAN DIEGO, Nov. 5 Conatus Pharmaceuticals Inc. ... CTS-1027 in,multiple models of hepatitis, an inflammatory liver ... today at the American Association for,the Study of ... significantly reduced liver damage following oral,administration in four ...
... Meeting of Connective Tissue Oncology, Society held in Seattle, ... perifosine as a single agent in patients with ... chemo-insensitive sarcomas, ... today announced that preliminary data demonstrating the,tolerability and clinical activity of ...
Cached Medicine Technology:Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6
(Date:9/22/2014)... September 22, 2014 WHO: LiveOps, ... and customer service solutions. , WHAT: The 10th ... on customer care for the connected consumer. Constant ... to offer new challenges and opportunities for customer ... attendees identify best practices, network and learn from ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... Tara Haelle ... News) -- Measuring how quickly a child,s brain processes ... to a new study. Observing children,s brainwaves ... currently possible, the study authors reported. "The finding ... is associated with autism severity is hugely promising," said ...
(Date:9/22/2014)... September 22, 2014 The “ Ztylus ” ... Tech Report , which reviews and features the latest technology ... of NewsWatch and technology expert, conducted the review and shared ... snap-in lens kit that gives users four lens options for ... part of its monthly Tech Report, which reviews and features ...
(Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
Breaking Medicine News(10 mins):Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... receive fewer blood transfusions do just as well as those ... of blood transfusions varies widely among U.S. hospitals. The ... Journal of the American Medical Association . In ...
... murine leukemia virusrelated virus (XMRV) has been the subject ... conflicting reports have created an unclear picture of XMRV,s ... in the November 15 issue of The Journal ... supports a possible link between XMRV and prostate cancer ...
... molecule they designed can block activation of a gene in ... those cancer cells to survive chemotherapy. Without the ... to be protected from the toxic effects of chemotherapy drugs. ... protecting the cells, the research suggests. As a result, more ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Oct. ... cancer patients treated with bisphosphonate drugs such as Aredia or ... be at higher risk for the irregular heartbeat known as ... atrial fibrillation, the upper chambers of the heart beat chaotically, ...
... results of a large Phase-III clinical trial have shown ... with a hard-to-treat group of rare cancers that affect ... the European Society for Medical Oncology (ESMO), Dr Marianne ... everolimus improved progression-free survival by 5.1 months in patients ...
... of breast cancer can lead some women to wonder if ... of more than 85,000 postmenopausal women, published in BioMed Central,s ... regular physical activity, maintaining a healthy weight, and drinking less ... a family history of the disease. The University of ...
Cached Medicine News:Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 2Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
... ChartingPlus proves itself to over 2,000 medical ... with the user in mind, ChartingPlus relies ... and dynamic features to improve documentation quality ... Our medical content is specific ...
Medicine Products: